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ABSTRACT
Objectives  HLA-DRB1*03 is strongly associated with 
anti-Jo-1-positive idiopathic inﬂ  ammatory myopathies (IIM) 
and there is now increasing evidence that Jo-1 antigen is 
preferentially expressed in lung tissue. This study examined 
whether smoking was associated with the development of 
anti-Jo-1 antibodies in HLA-DRB1*03-positive IIM.
Methods  IIM cases were selected with concurrent 
information regarding HLA-DRB1 status, smoking history 
and anti-Jo-1 antibody status. DNA was genotyped 
at DRB1 using a commercial sequence-speciﬁ  c 
oligonucleotide kit. Anti-Jo-1 antibody status was 
established using a line blot assay or immunoprecipitation.
Results  557 Caucasian IIM patients were recruited from 
Hungary (181), UK (99), Sweden (94) and Czech Republic 
(183). Smoking frequency was increased in anti-Jo-1-
positive IIM cases, and reached statistical signiﬁ  cance in 
Hungarian IIM (45% Jo-1-positive vs 17% Jo-1-negative, 
OR 3.94, 95% CI 1.53 to 9.89, p<0.0001). A strong 
association between HLA-DRB1*03 and anti-Jo-1 
status was observed across all four cohorts (DRB1*03 
frequency: 74% Jo-1-positive vs 35% Jo-1-negative, OR 
5.55, 95% CI 3.42 to 9.14, p<0.0001). The frequency of 
HLA-DRB1*03 was increased in smokers. The frequency 
of anti-Jo-1 was increased in DRB1*03-positive smokers 
vs DRB1*03-negative non-smokers (42% vs 8%, OR 7.75, 
95% CI 4.21 to 14.28, p<0.0001) and DRB1*03-positive 
non-smokers (42% vs 31%, p=0.08). In DRB1*03-
negative patients, anti-Jo-1 status between smokers and 
non-smokers was not signiﬁ  cantly different. No signiﬁ  cant 
interaction was noted between smoking and DRB1*03 
status using anti-Jo-1 as the outcome measure.
Conclusion  Smoking appears to be associated with 
an increased risk of possession of anti-Jo-1 in HLA-
DRB1*03-positive IIM cases. The authors hypothesise 
that an interaction between HLA-DRB1*03 and smoking 
may prime the development of anti-Jo-1 antibodies.
The idiopathic inﬂ   ammatory myopathies (IIM) 
are a group of rare and heterogenous autoimmune 
diseases characterised by inﬂ  ammation of skeletal 
muscle, other organ systems and associated with 
signiﬁ  cant co-morbidities. The aetiopathology of 
IIM remains poorly understood, but is likely due 
to interactions between genetic and environmental 
factors.1 IIM may be broadly classiﬁ  ed according to 
the traditional clinical subtypes: polymyositis, der-
matomyositis, myositis overlapping with another 
connective tissue disease (CTD), inclusion body 
myositis and juvenile dermatomyositis.
However, serological status according to cir-
culating myositis-speciﬁ   c antibodies (MSA) or 
myositis-associated antibodies (MAA) is being 
increasingly used in the classiﬁ  cation of IIM sub-
types, and often correlates with well-deﬁ  ned IIM 
clinical phenotypes. For example, anti-aminoacyl 
transfer RNA synthetase antibodies are highly 
speciﬁ   c for IIM and deﬁ   ne a clinical subtype 
labelled the ‘anti-synthetase syndrome’, charac-
terised by Raynaud’s phenomenon, mechanics’ 
hands, arthropathy, interstitial lung disease and 
myositis.2 The most frequently found anti-amino-
acyl tRNA synthetase antibody is the anti-histidyl 
tRNA synthetase (Jo-1) antibody. Alleles forming 
part of the Caucasian MHC 8.1 common ances-
tral haplotype (HLA-A1-B8-Cw7-DRB1*0301-
DQA1*0501-C4A*Q0) occur in strong linkage 
disequilibrium within Caucasian populations in 
northern and western Europe, and represent risk 
factors for a large number of immunopathological 
diseases.3 To date, the 8.1 common ancestral hap-
lotype has also been identiﬁ  ed as the major risk 
factor in IIM.2 4–11 HLA alleles are also associated 
with the development of MSA/MAA in IIM, and 
the strong association of anti-aminoacyl tRNA 
synthetase antibodies and alleles comprising the 
8.1 common ancestral haplotype has been con-
ﬁ  rmed in several IIM studies.2 8 12–15
The question arises as to whether and how anti-
Jo-1, an antibody against a ubiquitous cytoplas-
mic antigen, may play a pathogenic role in IIM. In 
the development of rheumatoid arthritis (RA), an 
interaction between smoking and alleles forming 
the HLA shared epitope is thought to prime the 
development of anti-citrulline-positive antibod-
ies.16 That Jo-1 is preferentially expressed in lung 
tissue17 18 is of potential relevance, bearing in mind 
that interstitial lung disease may be present in up to 
70% of anti-Jo-1-positive patients.19
The current study investigated the hypothesis that 
a gene–environmental interaction between HLA-
DRB1*03 and smoking could be of relevance in the 
development of anti-Jo-1 antibody-positive IIM.
▶ Additional  supplementary 
tables is published online only. 
To view the ﬁ  les please visit the 
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distribution between the cohorts (p=0.065). Fifty per cent of the 
patients were classiﬁ  ed as having polymyositis, 38% dermato-
myositis and 12% myositis–CTD overlap disease. A stratiﬁ  ca-
tion of clinical subgroup status by each participating country 
is summarised in table 1. An overall difference was present in 
the distribution of clinical subgroups (p<0.0001). Comparing the 
Hungarian cohort with other countries combined, the frequency 
of dermatomyositis was lower and myositis–CTD overlap 
higher in the Hungarian group. Within the Czech cohort, the der-
matomyositis frequency was higher and myositis–CTD overlap 
frequency lower. Some variation was noted in the frequency of 
HLA-DRB1*03 between the European cohorts (Hungary, 32.0%; 
Czech Republic, 43.2%; Sweden, 54.3%; UK, 52.5%; see supple-
mentary table S1, available online only).
Frequency of smoking and anti-Jo-1
The frequency of anti-Jo-1 antibodies was 21% for the overall 
group (table 2). The highest frequency was noted in the Czech 
cohort, and the lowest in the Swedish cohort. The frequency of 
anti-Jo-1 between the countries was broadly similar, although a 
signiﬁ  cant difference was noted in the overall distribution. The 
overall frequency of ‘ever smoking’ was 39% and an overall signiﬁ  -
cant difference was noted for the distribution of smoking between 
the countries. The lowest frequency of ever-smokers was noted in 
the Hungarian cohort, compared with the highest frequency being 
seen in the UK cohort. No signiﬁ  cant differences in the frequency 
of smoking were noted across the clinical subgroups.
Relationship between smoking and anti-Jo-1
The frequency of smoking was increased in anti-Jo-1-positive 
IIM cases across all four cohorts (smoking frequency 50% Jo-1-
positive cases vs 36% Jo-1-negative cases, OR 1.83, 95%CI 1.18 
to 2.83, p=0.004). This association also reached statistical sig-
niﬁ  cance in the case of the Hungarian IIM group (smoking fre-
quency 45% Jo-1-positive cases vs 17% Jo-1-negative cases, OR 
3.94, 95% CI 1.53 to 9.89, p=0.0009).
METHODS
Subjects
Five hundred and ﬁ  fty-seven adult-onset IIM patients, aged 18 
years of age or older at disease onset, were recruited from four 
European countries, UK, Sweden, Hungary and Czech Republic.2 
Patients with polymyositis or dermatomyositis had probable or 
deﬁ  nite myositis, according to the Bohan and Peter criteria.20 21 
Patients with myositis–CTD overlap either had their primary 
disease with probable/deﬁ   nite myositis according to Bohan 
and Peter,20 21 or had possible myositis but additionally had a 
conﬁ  rmed MSA/MAA.22 The collection of data and blood from 
patients was undertaken under the regulation of the relevant 
local research ethics committee, informed consent having been 
obtained according to the Declaration of Helsinki. Smoking 
history was ascertained through a retrospective questionnaire 
including the statement, ‘Have you ever smoked as much as one 
cigarette a day for as long as a year?’.
Anti-Jo-1 autoantibody testing
Serum was obtained from all patients for the determination 
of MSA including anti-Jo-1 antibodies. Sera from the Czech, 
Hungarian and Swedish cohorts were tested for antibodies to 
Jo-1 using a line-immunoassay system (Euroimmun, Lubeck, 
Germany). Brieﬂ  y, diluted patient serum was incubated on a 
rocker with a membrane strip with autoantigens located on 
nitrocellulose pads. After incubation and washing, bound anti-
body was detected using a speciﬁ  c anti-IgG antibody linked to 
an enzyme and visualised using a chromogenic reaction. This 
was performed according to the manufacturer’s instruction using 
the Euroblot-master automated processor (Euroimmun). Assays 
were visually interpreted by comparison with known negative 
and positive control samples. In the case of the UK samples, 
detection was made by radio-immunoprecipitation, as previ-
ously described.2 23 For anti-Jo-1 testing, the line-immunoassay 
system and radio-immunoprecipitation are known to correlate 
well with each other.24
Genotyping
DNA was extracted using standard phenol-chloroform or salt-
ing-out methods from a peripheral whole blood sample obtained 
from all cases. As data were readily available for HLA-DRB1 
across the four European cohorts, this particular loci was chosen 
for further investigation. Cases were broad-speciﬁ  city typed at 
the HLA-DRB1 loci, using commercially available kits.
Statistical analyses
Individual associations were derived from 2×2 contingency 
tables using the χ2 test, or two-tailed Fisher’s exact test when 
individual cells valued ﬁ  ve or less. Data were expressed as OR 
with exact 95% CI. Pointwise p values were not corrected as 
the association with HLA-DRB1*03 and IIM is well established 
in the literature.25 26 The described analyses were also repeated 
after stratiﬁ  cation by smoking and anti-Jo-1 status using multino-
mial logistic regression. The statistical package Stata (release 9.2) 
was used to perform statistical analysis.
RESULTS
Clinical subgroups
A total of 557 Caucasian adult-onset IIM patients (women 75%) 
was recruited from the following countries: Hungary (181), Czech 
Republic (183), Sweden (94), UK (99) (table 1). The median age 
of disease onset was 48 years (interquartile range 37–58). No 
signiﬁ  cant difference was noted in the gender or age at onset 
Table 1  IIM subgroup frequencies by country
Polymyositis Dermatomyositis Overlap Total
  n (%) n (%) n (%) n (%)
Hungary 101 (56) 42 (23)* 38 (21)† 181
Czech Republic 82 (45) 95 (52)‡ 6 (3)§ 183
Sweden 53 (56) 37 (39) 4 (4) 94
UK 40 (40) 39 (39) 20 (20) 99
Total 276 (50) 213 (38) 68 (12) 557
Comparing country with data from other countries combined: *Hungary: 
dermatomyositis versus polymyositis plus overlap: OR 0.36, 95% CI 0.24 to 0.54, 
corrected probability pcorr<0.0001; †Hungary: overlap versus polymyositis plus 
dermatomyositis: OR 3.06, 95% CI 1.83 to 5.14, pcorr<0.0001; ‡Czech Republic: 
dermatomyositis versus polymyositis plus overlap: OR 2.34, 95% CI 1.63 to 3.37, 
pcorr<0.0001; §Czech Republic: overlap versus polymyositis plus dermatomyositis: 
0.17, 95% CI 0.07 to 0.40, pcorr<0.0001.
IIM, idiopathic inﬂ  ammatory myopathy.
Table 2  Frequency of anti-Jo-1 and smoking status by country
Country
Anti-Jo-1 present Smoking ever
n (%) n (%)
Hungary 29 (16) 39 (22)
Czech Republic 50 (27) 71 (39)
Sweden 14 (15) 51 (54)
UK 22 (22) 55 (56)
Total 115 (21) 216 (39)
Comparison between countries: anti-Jo-1, overall p value 0.026. Smoking status, overall 
p value <0.0001.
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disease. Intriguingly, it was observed that the frequency of 
smoking was increased in anti-Jo-1-positive IIM cases across all 
four cohorts. The frequency of HLA-DRB1*03 was signiﬁ  cantly 
increased in IIM patients who were smokers in the Hungarian 
cohort. The frequency of anti-Jo-1 antibody was in fact high-
est in HLA-DRB1*03-positive smokers compared with the other 
groups. These ﬁ  ndings therefore suggest that smoking may only 
confer a risk of IIM in HLA-DRB1*03-positive individuals, or 
alternatively that smoking is a confounding variable for another 
factor that we did not investigate, for example, interstitial lung 
disease. Using a statistical interaction term, a relationship was 
not established between smoking and HLA-DRB1*03, but nev-
ertheless these results do suggest that there is an additional risk 
of the development of anti-Jo-1 in HLA-DRB1*03-positive cases 
who are ever-smokers.
The design of the study implies a number of limitations. 
Environmental triggers may have conferred risk years before 
IIM onset, therefore it would have been desirable to quantify 
the number of cigarettes and at what point they were smoked 
before the onset of IIM accurately. This would have allowed an 
examination of any cumulative effects of smoking on risk and 
to assess any temporal relationship of smoking with IIM onset 
or the commencement of anti-Jo-1 positivity. Examining these 
issues would, however, only be possible as part of a detailed 
prospective study. Our study was able to establish that smok-
ing does appear to represent a risk factor for the development 
of anti-Jo-1 antibodies, but due to a lack of a matched control 
population, we were not able to establish that smoking was a 
risk factor per se for IIM, as has been demonstrated in other 
autoimmune diseases.16 27 We aim to address this issue as part 
of a future study. Furthermore, this particular study has not 
examined other possible MSA/MAA as part of an interaction 
with smoking. It is possible that in this study, HLA-DRB1*03 
may be a marker for a different allele in which linkage dis-
equilibrium is shared. A further issue is the heterogeneity of 
the HLA class II distribution and the variation of smoking fre-
quency between the European populations, which will have 
affected the consistency of the results. Overall, a gene–envi-
ronmental interaction between HLA-DRB1*03 and smoking 
Relationship between HLA-DRB1*03 and anti-Jo-1
As expected from previous work,2 15 a strong association 
between HLA-DRB1*03 and anti-Jo-1 status was observed 
across all four cohorts combined (DRB1*03 frequency 74% Jo-1-
positive cases vs 35% Jo-1-negative cases, OR 5.55, 95% CI 3.42 
to 9.14, p=1.3×10−14).
Relationship between HLA-DRB1*03 and smoking
HLA-DRB1*03 was further examined by smoking status. The 
frequency of HLA-DRB1*03 was increased in smokers, and this 
association again reached statistical signiﬁ  cance in Hungarian 
IIM (DRB1*03 frequency 59% smokers vs 25% non-smokers, 
OR 4.39, 95% CI 1.96 to 9.92, p<0.00001).
Investigation of risk of developing anti-Jo-1 antibody conferred 
by HLA-DRB1*03 and smoking
An analysis was then conducted to examine further the interre-
lationship between smoking and HLA-DRB1*03, and the risk of 
the development of anti-Jo-1 antibodies. For the purposes of this 
analysis, and to maximise statistical power, the four EU cohorts 
were combined. The HLA-DRB1*03 negative/non-smokers were 
used as the reference group for these comparisons. The frequency 
of anti-Jo-1 was signiﬁ  cantly increased in both DRB1*03-positive 
smokers and non-smokers versus DRB1*03-negative non-smokers 
(table 3). In DRB1*03-negative patients, no signiﬁ  cant difference 
was noted in anti-Jo-1 status between smokers and non-smokers. 
The frequency of anti-Jo-1 was increased in the DRB1*03-positive 
group who smoked compared with DRB1*03-positive non-smok-
ers, although this trend did not achieve statistical signiﬁ  cance 
(p=0.08). A similar trend was noted when a separate analysis was 
made of men and women (table 4). An interaction term was then 
created between ever-smokers and DRB1*03 status, using anti-
Jo-1 as the outcome measure, but no multiplicative effect was 
observed between smoking and DRB1*03.
DISCUSSION
In four independent European IIM cohorts, the frequency of 
anti-Jo-1 antibody was approximately 20% in adult-onset 
Table 3  Anti-Jo-1 status by smoking and HLA-DRB1*03 status
Smoking status DRB1*03 status
Anti-Jo-1 positive, 
n (%)
Anti-Jo-1 negative, 
n (%) OR, 95% CI p Value
Negative Negative 18 (8) 196 (92) 1.0
Negative Positive 39 (31) 88 (69) 4.83, 2.62 to 8.90 <0.0001
Positive Negative 11 (11) 92 (89) 1.30, 0.59 to 2.87 0.51
Positive Positive 47 (42) 66 (58) 7.75, 4.21 to 14.28 <0.0001
HLA-DRB1*03-positive cases assigned if they possess one or two copies of DRB1*03.
Table 4  Anti-Jo-1 status by smoking and HLA-DRB1*03 status, and by gender
Smoking status DRB1*03 status
Anti-Jo-1 positive, 
n (%)
Anti-Jo-1 negative, 
n (%) OR, 95% CI p Value
Men
Negative Negative 4 (10) 35 (90) 1.0
Negative Positive 6 (25) 18 (75) 2.92, 0.73 to 11.67 0.13
Positive Negative 6 (16) 32 (84) 1.64, 0.42 to 6.35 0.47
Positive Positive 15 (39) 23 (61) 5.70, 1.68 to 19.37 0.005
Women
Negative Negative 14 (8) 161 (92) 1.0
Negative Positive 33 (32) 70 (68) 5.42, 2.73 to 10.75 <0.0001
Positive Negative 5 (8) 60 (92) 0.96, 0.33 to 2.78 0.94
Positive Positive 32 (43) 43 (57) 8.56, 4.20 to 17.5 <0.0001
HLA-DRB1*03-positive cases assigned if they possess one or two copies of DRB1*03.
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on the multiplicative scale was not proved to be statistically 
signiﬁ  cant, but this may be due to a lack of statistical power. 
We also estimated the interaction between HLA-DRB1*03 and 
smoking on the additive scale (data not shown), in which there 
was a tendency towards an interaction but this was not statis-
tically signiﬁ  cant.
Smoking has been shown to induce disease development in 
other rheumatic diseases. A number of case–control and cohort 
studies have conﬁ  rmed the association of smoking with the 
development of RA. Furthermore, a large case–control study 
has conﬁ  rmed a high risk of developing anti-citrullinated anti-
body-positive RA conferred by a gene–environmental interac-
tion between smoking and HLA-DR shared epitope genes.16 A 
further remarkable ﬁ  nding in this study was a high detected 
proportion of citrulline-positive bronchoalveolar lavage cells 
in healthy smokers. A further study has shown an associa-
tion between smoking and systemic lupus erythematosus, and 
more speciﬁ  cally the occurrence of anti-double-stranded DNA 
antibodies.28
The question arises as to whether smoking may have aetio-
pathological signiﬁ   cance in IIM, for example, by inducing 
immunomodulatory effects in lung tissues. The Jo-1 antigen 
is known to be expressed in normal and cancerous lung tis-
sue from non-IIM individuals in higher amounts than observed 
in other tissues.17 Granzyme B, a serine protease, is a critical 
component of the cytotoxic T-cell granule exocytosis path-
way,29 and is thought to mediate muscle cell apoptosis.30 
Most autoantigens targeted in systemic autoimmune diseases, 
including several aminoacyl tRNA synthetases, are substrates of 
granzyme B. Jo-1 appears to be uniquely cleaved by granzyme 
B in position 48 of the N-terminal domain.31 Furthermore, a 
unique granzyme B-cleavable form of Jo-1 is found in alveolar 
epithelium but not in muscle tissue,18 and the expression of 
soluble granzyme B in peripheral blood CD8+ T cells appears 
to be increased in smokers with chronic obstructive pulmo-
nary disease.32
In conclusion, the current study has shown that smoking 
is associated with IIM patients who are either anti-Jo-1 anti-
body and/or HLA-DRB1*03 positive. There is a suggestion that 
the risk of the development of anti-Jo-1 antibodies is further 
increased in IIM patients who are both smokers and possess one 
or more copies of HLA-DRB1*03. This may have aetiological 
signiﬁ  cance in the development of IIM and may point towards 
a gene–environmental interaction. Future larger scale work is 
now required in larger patient cohorts, and in which the effects 
of other HLA genes and associated antibodies are testable with 
respect to smoking associations.
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